Skip Ribbon Commands
Skip to main content
Sign In

26257 MGMT Promoter Methylation, Tumor (MGMT)

MGMT Promoter Methylation, Tumor (MGMT)
Test Code: MGMTSO
Useful For

Prognostication of newly diagnosed glioblastomas

Identifying newly diagnosed glioblastomas that may respond to alkylating chemotherapy (ie, temozolomide)

Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years)​

MGMT promoter methylation status has prognostic and predictive value for glioblastoma patients. 

Specimen Requirements

Pathology report must accompany specimen in order for testing to be performed.

 Preferred:

Specimen Type: Tissue

Container/Tube: Tissue block

Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block. At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5-micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides.

 

Acceptable:

Specimen Type: Tissue sections

Slides: 1 stained and 5 unstained

Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 5 unstained, nonbaked 5-micron thick sections of the tumor. At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5 micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides. 

Specimen Stability Information
Specimen TypeTemperature
​Varies ​ ​​Ambient (preferred)
​Frozen
​Refrigerated
Rejection Criteria
Specimens that have been decalcified (all methods); specimens that have not been formalin-fixed, paraffin-embedded; bone marrow in EDTA
Interference

​Not all patients whose tumors have MGMT promoter methylation will respond to alkylating chemotherapy.

MGMT promoter methylation status should not be used as the sole determinant of alkylating therapy eligibility.

Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport AvailableMethodology/Instrumentation
​Mayo Clinic Laboratories​Weekly; Varies​7 days​Methylation-Specific Polymerase Chain Reaction (PCR) Analysis
Reference Lab
Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​An interpretive report will be provided.
Interpretation

​An interpretive report will be provided.

Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​81287​1
​88381​1​Slide Review
Ordering Applications
Ordering ApplicationDescription
​COM​MGMT Promoter Methylat Tumor
​Cerner​MGMT Promoter Methyl, T (MGMT)
​Centricity​MGMT Promoter Methyl, T (MGMT)
If the ordering application you are looking for is not listed, contact your local laboratory for assistance.
Specimen Requirements

Pathology report must accompany specimen in order for testing to be performed.

 Preferred:

Specimen Type: Tissue

Container/Tube: Tissue block

Collection Instructions: Submit a formalin-fixed, paraffin-embedded tissue block. At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5-micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides.

 

Acceptable:

Specimen Type: Tissue sections

Slides: 1 stained and 5 unstained

Collection Instructions: Submit 1 slide stained with hematoxylin and eosin and 5 unstained, nonbaked 5-micron thick sections of the tumor. At least 40% tumor is required for this assay. In general, a 6 mm x 3 mm area of tissue cut at 5 micron thickness is the minimum amount of tissue needed; this could be collected over multiple slides. 

Specimen Stability Information
Specimen TypeTemperature
​Varies ​ ​​Ambient (preferred)
​Frozen
​Refrigerated
Rejection Criteria
Specimens that have been decalcified (all methods); specimens that have not been formalin-fixed, paraffin-embedded; bone marrow in EDTA
Interference

​Not all patients whose tumors have MGMT promoter methylation will respond to alkylating chemotherapy.

MGMT promoter methylation status should not be used as the sole determinant of alkylating therapy eligibility.

Test results should be interpreted in context of clinical findings, tumor sampling, and other laboratory data. If results obtained do not match other clinical or laboratory findings, contact the laboratory for possible interpretation. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.

Useful For

Prognostication of newly diagnosed glioblastomas

Identifying newly diagnosed glioblastomas that may respond to alkylating chemotherapy (ie, temozolomide)

Guiding therapy decision making for newly diagnosed glioblastomas in elderly patients (>60 years)​

MGMT promoter methylation status has prognostic and predictive value for glioblastoma patients. 

Reference Range Information
Performing LocationReference Range
​Mayo Clinic Laboratories​An interpretive report will be provided.
Interpretation

​An interpretive report will be provided.

For more information visit:
Performing Laboratory Information
Performing LocationDay(s) Test PerformedReport AvailableMethodology/Instrumentation
​Mayo Clinic Laboratories​Weekly; Varies​7 days​Methylation-Specific Polymerase Chain Reaction (PCR) Analysis
Reference Lab
For billing questions, see Contacts
Outreach CPTs
CPTModifier
(if needed)
QuantityDescriptionComments
​81287​1
​88381​1​Slide Review
For most current information refer to the Marshfield Laboratory online reference manual.